China-based JW Therapeutics (HKG: 2126) has entered into a partnership with US firm 2seventy bio Inc. (NASDAQ: TSVT) to establish a cell therapy translational and clinical development platform. The collaboration aims to enhance the development of T-cell therapies in mainland China, Hong Kong, and Macau.
Initial Focus on MAGE-A4 T-Cell Receptor Program
The initial focus of the partnership will be on 2seventy’s MAGE-A4 T-cell receptor (TCR) program, which was previously co-developed with Regeneron. This program is designed to develop TCR-T cell therapies to treat MAGE-A4 positive solid tumors. MAGE-A4, a member of the cancer testis antigen MAGE family, is expressed in various solid tumors and is considered a potential target for anti-tumor therapy.
Agreement Details
Under the agreement, 2seventy will grant JW Therapeutics the development, manufacturing, and commercialization rights to its MAGE-A4 cell therapy program in mainland China, Hong Kong, and Macau. In return, JW Therapeutics will pay 2seventy undisclosed milestone payments and product income-based royalties. Additionally, 2seventy retains the rights to develop the product based on early clinical data acquired through the collaboration.
Future Outlook
With this partnership, JW Therapeutics and 2seventy bio are poised to advance the development of innovative T-cell therapies, leveraging their combined expertise to address significant unmet needs in oncology.-Fineline Info & Tech
